Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus
Background: Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). Rebamipide is an effective gastric cytoprotective agent, but there are few data on its usefulness in T2DM. The aim of this study is to evaluate the improvement of GI symptoms after rebamipide trea...
Gespeichert in:
| Veröffentlicht in: | Diabetes & metabolism journal 2016-06, Vol.40 (3), p.240 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | kor |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 240 |
| container_title | Diabetes & metabolism journal |
| container_volume | 40 |
| creator | Sejeong Park So Young Park Yu Jin Kim Soo Min Hong Suk Chon Seungjoon Oh Jeong-taek Woo Sung-woon Kim Young Seol Kim Sang Youl Rhee |
| description | Background: Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). Rebamipide is an effective gastric cytoprotective agent, but there are few data on its usefulness in T2DM. The aim of this study is to evaluate the improvement of GI symptoms after rebamipide treatment in patients with T2DM. Methods: Patients with T2DM and atypical GI symptoms were enrolled. They took rebamipide (100 mg thrice daily) for 12 weeks and filled out the diabetes bowel symptom questionnaire (DBSQ) before and after rebamipide treatment. The DBSQ consisted of 10 questions assessing the severity of GI symptoms by a 1 to 6 scoring system. Changes in the DBSQ scores before and after rebamipide treatment were analyzed to evaluate any improvements of GI symptoms. Results: A total of 107 patients were enrolled, and 84 patients completed the study. The mean age was 65.0±7.8, 26 patients were male (24.8%), the mean duration of T2DM was 14.71±9.12 years, and the mean glycosylated hemoglobin level was 6.97%±0.82%. The total DBSQ score was reduced significantly from 24.9±8.0 to 20.4±7.3 before and after rebamipide treatment (P |
| format | Article |
| fullrecord | <record><control><sourceid>kiss</sourceid><recordid>TN_cdi_kiss_primary_3439474</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><kiss_id>3439474</kiss_id><sourcerecordid>3439474</sourcerecordid><originalsourceid>FETCH-kiss_primary_34394743</originalsourceid><addsrcrecordid>eNp9i7sOgkAQAK_QRKJ8gc3-AAlwBKRW1MbEKKUJOXSJG-9B2DOGv5fC2mqKmZmJIE2ljPK4KBciZKY2TvIk3sSFDMSt6jq8ewbXwQVbZainB4KzcFDsB0fWI3uySsN1NL13hoEsnJUntNP2If-EeuwRUtiRanHK4YRak3_zSsw7pRnDH5diva_q7TF6EXPTD2TUMDYyk2VWZPK__QKqaj3f</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus</title><source>KoreaMed Synapse</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>KoreaMed Open Access</source><source>PubMed Central</source><creator>Sejeong Park ; So Young Park ; Yu Jin Kim ; Soo Min Hong ; Suk Chon ; Seungjoon Oh ; Jeong-taek Woo ; Sung-woon Kim ; Young Seol Kim ; Sang Youl Rhee</creator><creatorcontrib>Sejeong Park ; So Young Park ; Yu Jin Kim ; Soo Min Hong ; Suk Chon ; Seungjoon Oh ; Jeong-taek Woo ; Sung-woon Kim ; Young Seol Kim ; Sang Youl Rhee</creatorcontrib><description>Background: Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). Rebamipide is an effective gastric cytoprotective agent, but there are few data on its usefulness in T2DM. The aim of this study is to evaluate the improvement of GI symptoms after rebamipide treatment in patients with T2DM. Methods: Patients with T2DM and atypical GI symptoms were enrolled. They took rebamipide (100 mg thrice daily) for 12 weeks and filled out the diabetes bowel symptom questionnaire (DBSQ) before and after rebamipide treatment. The DBSQ consisted of 10 questions assessing the severity of GI symptoms by a 1 to 6 scoring system. Changes in the DBSQ scores before and after rebamipide treatment were analyzed to evaluate any improvements of GI symptoms. Results: A total of 107 patients were enrolled, and 84 patients completed the study. The mean age was 65.0±7.8, 26 patients were male (24.8%), the mean duration of T2DM was 14.71±9.12 years, and the mean glycosylated hemoglobin level was 6.97%±0.82%. The total DBSQ score was reduced significantly from 24.9±8.0 to 20.4±7.3 before and after rebamipide treatment (P<0.001). The DBSQ scores associated with reflux symptoms, indigestion, nausea or vomiting, abdominal bloating or distension, peptic ulcer, abdominal pain, and constipation were improved after rebamipide treatment (P<0.05). However, there were no significant changes in symptoms associated with irritable bowel syndrome, diarrhea, and anal incontinence. No severe adverse events were reported throughout the study. Conclusion: Rebamipide treatment for 12 weeks improved atypical GI symptoms in patients with T2DM.</description><identifier>ISSN: 2233-6079</identifier><language>kor</language><publisher>대한당뇨병학회</publisher><subject>Diabetes mellitus ; Gastrointestinal diseases ; Rebamipide ; type 2</subject><ispartof>Diabetes & metabolism journal, 2016-06, Vol.40 (3), p.240</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids></links><search><creatorcontrib>Sejeong Park</creatorcontrib><creatorcontrib>So Young Park</creatorcontrib><creatorcontrib>Yu Jin Kim</creatorcontrib><creatorcontrib>Soo Min Hong</creatorcontrib><creatorcontrib>Suk Chon</creatorcontrib><creatorcontrib>Seungjoon Oh</creatorcontrib><creatorcontrib>Jeong-taek Woo</creatorcontrib><creatorcontrib>Sung-woon Kim</creatorcontrib><creatorcontrib>Young Seol Kim</creatorcontrib><creatorcontrib>Sang Youl Rhee</creatorcontrib><title>Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus</title><title>Diabetes & metabolism journal</title><addtitle>Diabetes and Metabolism Journal (DMJ)</addtitle><description>Background: Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). Rebamipide is an effective gastric cytoprotective agent, but there are few data on its usefulness in T2DM. The aim of this study is to evaluate the improvement of GI symptoms after rebamipide treatment in patients with T2DM. Methods: Patients with T2DM and atypical GI symptoms were enrolled. They took rebamipide (100 mg thrice daily) for 12 weeks and filled out the diabetes bowel symptom questionnaire (DBSQ) before and after rebamipide treatment. The DBSQ consisted of 10 questions assessing the severity of GI symptoms by a 1 to 6 scoring system. Changes in the DBSQ scores before and after rebamipide treatment were analyzed to evaluate any improvements of GI symptoms. Results: A total of 107 patients were enrolled, and 84 patients completed the study. The mean age was 65.0±7.8, 26 patients were male (24.8%), the mean duration of T2DM was 14.71±9.12 years, and the mean glycosylated hemoglobin level was 6.97%±0.82%. The total DBSQ score was reduced significantly from 24.9±8.0 to 20.4±7.3 before and after rebamipide treatment (P<0.001). The DBSQ scores associated with reflux symptoms, indigestion, nausea or vomiting, abdominal bloating or distension, peptic ulcer, abdominal pain, and constipation were improved after rebamipide treatment (P<0.05). However, there were no significant changes in symptoms associated with irritable bowel syndrome, diarrhea, and anal incontinence. No severe adverse events were reported throughout the study. Conclusion: Rebamipide treatment for 12 weeks improved atypical GI symptoms in patients with T2DM.</description><subject>Diabetes mellitus</subject><subject>Gastrointestinal diseases</subject><subject>Rebamipide</subject><subject>type 2</subject><issn>2233-6079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9i7sOgkAQAK_QRKJ8gc3-AAlwBKRW1MbEKKUJOXSJG-9B2DOGv5fC2mqKmZmJIE2ljPK4KBciZKY2TvIk3sSFDMSt6jq8ewbXwQVbZainB4KzcFDsB0fWI3uySsN1NL13hoEsnJUntNP2If-EeuwRUtiRanHK4YRak3_zSsw7pRnDH5diva_q7TF6EXPTD2TUMDYyk2VWZPK__QKqaj3f</recordid><startdate>20160630</startdate><enddate>20160630</enddate><creator>Sejeong Park</creator><creator>So Young Park</creator><creator>Yu Jin Kim</creator><creator>Soo Min Hong</creator><creator>Suk Chon</creator><creator>Seungjoon Oh</creator><creator>Jeong-taek Woo</creator><creator>Sung-woon Kim</creator><creator>Young Seol Kim</creator><creator>Sang Youl Rhee</creator><general>대한당뇨병학회</general><scope>HZB</scope><scope>Q5X</scope></search><sort><creationdate>20160630</creationdate><title>Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus</title><author>Sejeong Park ; So Young Park ; Yu Jin Kim ; Soo Min Hong ; Suk Chon ; Seungjoon Oh ; Jeong-taek Woo ; Sung-woon Kim ; Young Seol Kim ; Sang Youl Rhee</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kiss_primary_34394743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2016</creationdate><topic>Diabetes mellitus</topic><topic>Gastrointestinal diseases</topic><topic>Rebamipide</topic><topic>type 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sejeong Park</creatorcontrib><creatorcontrib>So Young Park</creatorcontrib><creatorcontrib>Yu Jin Kim</creatorcontrib><creatorcontrib>Soo Min Hong</creatorcontrib><creatorcontrib>Suk Chon</creatorcontrib><creatorcontrib>Seungjoon Oh</creatorcontrib><creatorcontrib>Jeong-taek Woo</creatorcontrib><creatorcontrib>Sung-woon Kim</creatorcontrib><creatorcontrib>Young Seol Kim</creatorcontrib><creatorcontrib>Sang Youl Rhee</creatorcontrib><collection>Korean Studies Information Service System (KISS)</collection><collection>Korean Studies Information Service System (KISS) B-Type</collection><jtitle>Diabetes & metabolism journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sejeong Park</au><au>So Young Park</au><au>Yu Jin Kim</au><au>Soo Min Hong</au><au>Suk Chon</au><au>Seungjoon Oh</au><au>Jeong-taek Woo</au><au>Sung-woon Kim</au><au>Young Seol Kim</au><au>Sang Youl Rhee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus</atitle><jtitle>Diabetes & metabolism journal</jtitle><addtitle>Diabetes and Metabolism Journal (DMJ)</addtitle><date>2016-06-30</date><risdate>2016</risdate><volume>40</volume><issue>3</issue><spage>240</spage><pages>240-</pages><issn>2233-6079</issn><abstract>Background: Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). Rebamipide is an effective gastric cytoprotective agent, but there are few data on its usefulness in T2DM. The aim of this study is to evaluate the improvement of GI symptoms after rebamipide treatment in patients with T2DM. Methods: Patients with T2DM and atypical GI symptoms were enrolled. They took rebamipide (100 mg thrice daily) for 12 weeks and filled out the diabetes bowel symptom questionnaire (DBSQ) before and after rebamipide treatment. The DBSQ consisted of 10 questions assessing the severity of GI symptoms by a 1 to 6 scoring system. Changes in the DBSQ scores before and after rebamipide treatment were analyzed to evaluate any improvements of GI symptoms. Results: A total of 107 patients were enrolled, and 84 patients completed the study. The mean age was 65.0±7.8, 26 patients were male (24.8%), the mean duration of T2DM was 14.71±9.12 years, and the mean glycosylated hemoglobin level was 6.97%±0.82%. The total DBSQ score was reduced significantly from 24.9±8.0 to 20.4±7.3 before and after rebamipide treatment (P<0.001). The DBSQ scores associated with reflux symptoms, indigestion, nausea or vomiting, abdominal bloating or distension, peptic ulcer, abdominal pain, and constipation were improved after rebamipide treatment (P<0.05). However, there were no significant changes in symptoms associated with irritable bowel syndrome, diarrhea, and anal incontinence. No severe adverse events were reported throughout the study. Conclusion: Rebamipide treatment for 12 weeks improved atypical GI symptoms in patients with T2DM.</abstract><pub>대한당뇨병학회</pub><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2233-6079 |
| ispartof | Diabetes & metabolism journal, 2016-06, Vol.40 (3), p.240 |
| issn | 2233-6079 |
| language | kor |
| recordid | cdi_kiss_primary_3439474 |
| source | KoreaMed Synapse; DOAJ Directory of Open Access Journals; PubMed Central Open Access; KoreaMed Open Access; PubMed Central |
| subjects | Diabetes mellitus Gastrointestinal diseases Rebamipide type 2 |
| title | Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T21%3A56%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kiss&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Rebamipide%20on%20Gastrointestinal%20Symptoms%20in%20Patients%20with%20Type%202%20Diabetes%20Mellitus&rft.jtitle=Diabetes%20&%20metabolism%20journal&rft.au=Sejeong%20Park&rft.date=2016-06-30&rft.volume=40&rft.issue=3&rft.spage=240&rft.pages=240-&rft.issn=2233-6079&rft_id=info:doi/&rft_dat=%3Ckiss%3E3439474%3C/kiss%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_kiss_id=3439474&rfr_iscdi=true |